IDE

CodeSignal Announces New Advanced Assessment Capabilities Fueled by a $50M Series C Funding Led by Index Ventures

Thursday, September 16, 2021 - 3:00pm

This round, which brings CodeSignal's total funding to $87.5M, was led by Index Ventures , with additional participation from Menlo Ventures , Headline , and A Capital .

Key Points: 
  • This round, which brings CodeSignal's total funding to $87.5M, was led by Index Ventures , with additional participation from Menlo Ventures , Headline , and A Capital .
  • Likewise, employers can now assess all of an applicant's skills at the same time through a single coding task.
  • There is an amazing opportunity in front of us to change hiring culture and CodeSignal is the company making that happen."
  • Founded in 2015, CodeSignal is trusted by the world's most innovative tech firms, including Brex, Databricks, Facebook, Instacart, Robinhood, Upwork, and Zoom.

Neuros Medical Announces Completion of Enrollment in the QUEST Pivotal Clinical Study for Chronic Post-Amputation Pain

Wednesday, September 15, 2021 - 4:15pm

QUEST is designed to assess the safety & effectiveness of the Company's AltiusHigh-Frequency Nerve Block system to treat intractable post-amputation pain.

Key Points: 
  • QUEST is designed to assess the safety & effectiveness of the Company's AltiusHigh-Frequency Nerve Block system to treat intractable post-amputation pain.
  • Post-amputation pain is a significant unmet medical need, as existing treatment options are limited, and consist primarily of opioids and gabapentinoids.
  • Neuros Medical, a neuromodulation company, has developed the Altius system for the treatment of chronic post-amputation pain (phantom limb pain and residual limb pain).
  • Post-amputation pain includes both phantom limb and residual limb (or "stump") pain, and impacts nearly one million Americans.

The Eclipse Foundation Announces the Results of the 2021 Jakarta EE Developer Survey

Tuesday, September 14, 2021 - 12:00pm

The 2021 Jakarta EE Developer Survey Report is available to download on the Jakarta EE website.

Key Points: 
  • The 2021 Jakarta EE Developer Survey Report is available to download on the Jakarta EE website.
  • Java EE 8, Jakarta EE 8 and Jakarta EE 9 have now seen 75% adoption among respondents.
  • I was excited to see proof of wider mainstream adoption of Jakarta EE 8 and Jakarta EE 9, confirming community satisfaction ahead of the further innovations of Jakarta EE 10.
  • The 2021 Jakarta EE Developer survey highlights the continuing adoption of Jakarta EE by enterprises for cloud-native Java applications.

Nyxoah Announces U.S. FDA Breakthrough Device Designation Granted for the Genio® System for Obstructive Sleep Apnea and Complete Concentric Collapse

Tuesday, September 14, 2021 - 7:00am

According to the FDA, OSA is an irreversibly debilitating human disease for patients with sleep apnea.

Key Points: 
  • According to the FDA, OSA is an irreversibly debilitating human disease for patients with sleep apnea.
  • We are pleased to have received Breakthrough Device Designation for our proprietary Genio system for OSA patients with CCC, recognizing that Obstructive Sleep Apnea is an irreversibly debilitating condition.
  • Nyxoah will submit full BETTER SLEEP study data to a medical journal for publication and announce results following further analyses.
  • Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA).

Nyxoah Announces Participation in the Cantor 2021 Virtual Global Healthcare Conference

Monday, September 13, 2021 - 9:30pm

Mont-Saint-Guibert (Belgium), September 13, 2021, 10:30 pm CET / 4:30 pm ET Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (Nyxoah or the Company), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Olivier Taelman, Chief Executive Officer, will participate at the Cantor 2021 Global Healthcare Conference on Tuesday, September 28, 2021, with a virtual presentation at 4:00 pm CET/10:00 am ET.

Key Points: 
  • Mont-Saint-Guibert (Belgium), September 13, 2021, 10:30 pm CET / 4:30 pm ET Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (Nyxoah or the Company), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Olivier Taelman, Chief Executive Officer, will participate at the Cantor 2021 Global Healthcare Conference on Tuesday, September 28, 2021, with a virtual presentation at 4:00 pm CET/10:00 am ET.
  • Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA).
  • Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
  • Nyxoah completed two successful IPOs: on Euronext in September 2020 and NASDAQ in July 2021.

NuVasive Simplify Cervical Disc Data Published In International Journal Of Spine Surgery

Thursday, September 9, 2021 - 12:00pm

SAN DIEGO, Sept. 9, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the NuVasive Simplify Cervical Disc one-level U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) study data was recently published in the International Journal of Spine Surgery .

Key Points: 
  • SAN DIEGO, Sept. 9, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the NuVasive Simplify Cervical Disc one-level U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) study data was recently published in the International Journal of Spine Surgery .
  • "This recent peer-reviewed publication validates the strong clinical data behind the Simplify Cervical Disc and why this is the most clinically effective technology in the cTDR procedure segment," said Kyle Malone, vice president of Clinical, Medical, and Regulatory Affairs at NuVasive.
  • "As we continue to pursue Simplify Cervical Disc clinical data, we are encouraged by these results to support our commitment to outcome-driven innovation in spine surgery that benefits surgeons, hospitals, andmost importantlypatients."
  • The Simplify Cervical Disc is part of the NuVasive C360 portfolio , which offers comprehensive, procedurally integrated solutions for the cervical spine across ACDF, posterior cervical fusion, and cTDR procedures.

ADLINK Launches Edge Vision Analytics (EVA) Software Development Kit (SDK) to Accelerate Edge AI Vision

Wednesday, September 8, 2021 - 3:00pm

EVA SDK's integrated development environment (IDE) is currently built into ADLINK's NEON series AI smart cameras and EOS series AI vision systems for AI-enabled machine vision project development.

Key Points: 
  • EVA SDK's integrated development environment (IDE) is currently built into ADLINK's NEON series AI smart cameras and EOS series AI vision systems for AI-enabled machine vision project development.
  • "EVA SDK is a one-API framework that lets users build edge AI vision applications with low coding efforts," said Chia-Wei Yang, Head of Edge Vision Business Center, ADLINK.
  • Using EVA SDK, developers can build an AI vision application quickly without AI expertise.
  • ADLINK, an industrial AI vision expert with 25 years of experience in machine vision, continually provides application-oriented, ready-to-develop AI models to manufacturers.

atHeart Medical Appoints Seasoned Medtech Executive Andrew Cleeland to Board of Directors

Wednesday, September 8, 2021 - 12:01pm

BAAR, Switzerland and MOUNTAIN VIEW, Calif., Sept. 8, 2021 /PRNewswire/ -- atHeart Medical, a medical device company dedicated to establishing the new standard of care for closure of atrial septal defects (ASD), today announced the appointment of Andrew Cleeland to the company's Board of Directors. With over thirty years of experience, including specific expertise bringing game-changing technologies to market, Mr. Cleeland joins as the company builds momentum for the ASCENT-ASD U.S. investigational device exemption (IDE) trial studying the safety and efficacy of its reSept™ ASD Occluder technology.

Key Points: 
  • BAAR, Switzerland and MOUNTAIN VIEW, Calif., Sept. 8, 2021 /PRNewswire/ -- atHeart Medical , a medical device company dedicated to establishing the new standard of care for closure of atrial septal defects (ASD), today announced the appointment of Andrew Cleeland to the company's Board of Directors.
  • The company's next-generation, metal-free, bioresorbable frame design is a novel approach in the structural heart space," said Mr. Cleeland.
  • He currently serves on the board of three venture-funded companies, Saluda Medical, Zenflow, Inc. (chairman) and MMI S.p.A. (chairman).Mr.
  • He is a proven medtech leader with a strong passion for championing novel healthcare solutions," commented Laurent Grandidier, CEO of atHeart Medical.

atHeart Medical Appoints Seasoned Medtech Executive Andrew Cleeland to Board of Directors

Wednesday, September 8, 2021 - 12:01pm

BAAR, Switzerland and MOUNTAIN VIEW, Calif., Sept. 8, 2021 /PRNewswire/ -- atHeart Medical , a medical device company dedicated to establishing the new standard of care for closure of atrial septal defects (ASD), today announced the appointment of Andrew Cleeland to the company's Board of Directors.

Key Points: 
  • BAAR, Switzerland and MOUNTAIN VIEW, Calif., Sept. 8, 2021 /PRNewswire/ -- atHeart Medical , a medical device company dedicated to establishing the new standard of care for closure of atrial septal defects (ASD), today announced the appointment of Andrew Cleeland to the company's Board of Directors.
  • The company's next-generation, metal-free, bioresorbable frame design is a novel approach in the structural heart space," said Mr. Cleeland.
  • He currently serves on the board of three venture-funded companies, Saluda Medical, Zenflow, Inc. (chairman) and MMI S.p.A. (chairman).Mr.
  • He is a proven medtech leader with a strong passion for championing novel healthcare solutions," commented Laurent Grandidier, CEO of atHeart Medical.

Aethlon Medical to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Tuesday, September 7, 2021 - 1:01pm

The Aethlon Hemopurifier is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections.

Key Points: 
  • The Aethlon Hemopurifier is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections.
  • In cancer, the Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression.
  • The EFS is being conducted at the University of Pittsburgh Medical Center Hillman Cancer Center.
  • The Hemopurifier also holds a Breakthrough Device designation related to life-threatening viruses that are not addressed with approved therapies.